Opinion

Video

The Evolving Treatment Landscape in BCG-Unresponsive NMIBC

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

Bladder cancer experts discuss the evolving treatment landscape in BCG-unresponsive NMIBC and give an overview of TAR-200, an emerging therapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: Redefining treatment for LG-IR-NMIBC
      Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
      Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
      Anne Schuckman, MD, highlights promising new developments in NMIBC
      Anne Schuckman, MD, highlights promising new developments in NMIBC
      Vignesh Packiam, MD, on choosing between options in NMIBC
      Vignesh Packiam, MD, on choosing between options in NMIBC
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      4 experts in this video
      Case 3: A 49-Year-Old Man With Recurrent Non–Muscle-Invasive Bladder Cancer
      Related Content
      FDA updates in urology: June 2025
      July 1st 2025

      FDA updates in urology: June 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from June 2025.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      June 30th 2025

      Phase 2 trial of TYRA-300 launches in LG-IR-NMIBC

      Hannah Clarke
      The primary end point for the trial is the complete response rate at 3 months.
      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
      May 26th 2022

      Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

      Urology Times staff
      “We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.
      FDA grants RMAT designation to detalimogene voraplasmid for high-risk NMIBC
      June 25th 2025

      FDA grants RMAT designation to detalimogene voraplasmid for high-risk NMIBC

      Hannah Clarke
      Detalimogene is currently under evaluation in the pivotal phase 1/2 LEGEND trial.
      From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance
      June 16th 2025

      From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance

      Anne K. Schuckman, MD Hannah Clarke
      Anne K. Schuckman, MD, describes the growing number of options in NMIBC and the impact of these therapies on clinical practice.
      © 2025 MJH Life Sciences

      All rights reserved.